Anzeige
Mehr »
Mittwoch, 04.03.2026 - Börsentäglich über 12.000 News
1.000.000 $ staatliche Förderung - Startet hier Kanadas nächster Lithium-Champion?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40DEH | ISIN: US09073Q3039 | Ticker-Symbol: 2F5
Frankfurt
03.03.26 | 15:25
0,700 Euro
-9,09 % -0,070
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SCINAI IMMUNOTHERAPEUTICS LTD ADR Chart 1 Jahr
5-Tage-Chart
SCINAI IMMUNOTHERAPEUTICS LTD ADR 5-Tage-Chart
RealtimeGeldBriefZeit
0,6850,69503.03.
0,6750,73503.03.

Aktuelle News zur SCINAI IMMUNOTHERAPEUTICS LTD Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
25.02.Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer14
25.02.Scinai receives expanded grant for robotic manufacturing system3
17.02.Scinai Immunotherapeutics Buys Recipharm Israel2
17.02.Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer1
SCINAI IMMUNOTHERAPEUTICS LTD Aktie jetzt für 0€ handeln
17.02.Scinai Immunotherapeutics Ltd.: Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm163JERUSALEM, Feb. 17, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing inflammation and immunology...
► Artikel lesen
23.12.25Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer-
02.12.25Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer2
02.12.25Scinai reports revenue growth as CDMO business expands2
02.12.25Scinai Immunotherapeutics Ltd.: Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances705JERUSALEM, Dec. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing innovative...
► Artikel lesen
13.11.25Scinai Immunotherapeutics beraumt jährliche Hauptversammlung für 22. Dezember an3
13.11.25Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer-
12.11.25Scinai Immunotherapeutics Ltd. - S-8, Securities to be offered to employees in employee benefit plans-
06.10.25Scinai receives $246,000 grant to expand biotech manufacturing4
06.10.25Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer1
22.09.25Scinai Immunotherapeutics Ltd. - F-1, Registration statement for certain foreign private issuers2
22.09.25Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer-
11.09.25Scinai Immunotherapeutics Ltd. - 6-K, Report of foreign issuer1
02.09.25Scinai Immunotherapeutics Ltd.: Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet356JERUSALEM, Sept. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing...
► Artikel lesen
05.06.25Scinai Immunotherapeutics Ltd.: Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.185The regulatory approval marks a key milestone toward the potential acquisition of Pincell, removing a major condition precedent under the option agreement and allowing...
► Artikel lesen
30.05.25Scinai Immunotherapeutics Ltd.: Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn322JERUSALEM, May 30th, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on...
► Artikel lesen
Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1